Clinical Trials Logo

Filter by:
NCT ID: NCT03198117 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)

Start date: April 25, 2017
Phase: N/A
Study type: Interventional

This study including two parts,one part is a randomized clinical trial design,another part is a registration study.

NCT ID: NCT03198091 Recruiting - Clinical trials for Coronary Heart Disease

Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris

Start date: March 30, 2017
Phase: N/A
Study type: Interventional

This registry is designed to investigate factors affecting the efficacy of Dun Ye Guan Xin Ning tablet on patients with stable angina. The potential hypothesis is that Dun Ye Guan Xin Ning has a better effect on different subgroup patients with certain characteristics.

NCT ID: NCT03198052 Not yet recruiting - Cancer Clinical Trials

PSCA-CAR-T or MUC1-CAR-T for Cancer With PSCA/MUC1 Expression

Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

The third generation of CAR-T cells that target PSCA or MUC1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the PSCA/MUC1-CAR-T cells in human cancer patients with PSCA or MUC1 expression.In this phase I study, the safety,tolerance, and preliminary efficacy of the PSCA/MUC1-CAR-T cell immunotherapy on human will firstly be tested.

NCT ID: NCT03197818 Recruiting - Clinical trials for COPD (Chronic Obstructive Pulmonary Disease)

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort® Turbuhaler® in terms of pulmonary function, as well as to assess its safety.

NCT ID: NCT03196986 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

MIL60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Start date: July 2017
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of MIL60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in chemotherapy-naive patients with metastatic or recurrent non-squamous NSCLC.

NCT ID: NCT03196869 Recruiting - Clinical trials for Locally Advanced Head and Neck Squamous Cell Carcinoma

the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer

Start date: April 7, 2017
Phase: Phase 2
Study type: Interventional

This study is to observe and compare the effect of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin chemoradiotherapy on dendritic cells subsets in the treatment of locally advanced head and neck squamous cell carcinoma.

NCT ID: NCT03196830 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma


Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.

NCT ID: NCT03196414 Recruiting - Multiple Myeloma Clinical Trials

Study of CART-138/BCMA Therapy for R/R Multiple Myeloma

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

To test the safety and efficacy of giving targeting CD138 or B-cell maturation antigen T cells in treating patients with CD138 or BCMA positive multiple myeloma that is refractory to further chemotherapy or relapsed(after stem cell transplantation or intensive chemotherapy).

NCT ID: NCT03196362 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes

Start date: December 1, 2016
Phase: Phase 4
Study type: Interventional

Short-term intensive insulin therapy (SIIT) induces glycemic remission in patients with newly diagnosed type 2 diabetes. But remission rate reduces over time. This study aims to investigate whether sequential treatments using fixed dose combination of pioglitazone/metformin (15mg/500mg) after SIIT can improve clinical outcomes inpatients with newly diagnosed type 2 diabetes. We plan to include 50 patients with newly diagnosed type 2 diabetes who are drug naïve and meet the inclusive criteria will be enrolled. After baseline assessments, SIIT will be applied to all patients using insulin pump to achieve and maintain euglycemia for 2 weeks. After completion of intensive treatment, insulin pump will be stopped. Patients were randomly assigned into either of the following two groups: PIO/MET group: pioglitazone/metformin (15mg/500mg) will be orally administrated twice daily to the subjects for 12 weeks; placebo group: placebo is given twice daily to all subjects for 12 weeks. Afterwards, patients will be followed up for 48 weeks. Primary endpoint is difference in remission rate at the end of study. Secondary endpoints include proportion of patients who achieve glycosylated hemoglobin A1C <7% at the end of study; differences in β-cell function , insulin sensitivity and incidence of adverse events among treatment groups.

NCT ID: NCT03195621 Recruiting - Clinical trials for Coronary Artery Disease

Critical Treatment of Coronary Artery Disease

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

Identifying the critical lesion of coronary artery disease and determining the interventional plan are significant for reducing adverse cardiovascular adverse events. The assessment of critical lesion requires the consideration of plaque morphology, tissue composition, and endometrial stress which leading to rupture. In summary, accurate assessment of critical lesions has high application value. In this study, patients with critical coronary artery disease were divided into two groups: an accurate assessment group and a simple assessment group, with the aim to compare the diagnosis and treatment efficiency as well as prognosis, potential cardiovascular risk, possible "excessive" intervention.